Related Experiment Video
Updated: May 14, 2026
07:03
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Adviti Naik1, Aleš Belič, Ulrich M Zanger
1Faculty of Computer Sciences and Informatics, University of Ljubljana Ljubljana, Slovenia.
Frontiers in Genetics
|January 25, 2013
Summary
Non-alcoholic fatty liver disease (NAFLD) disrupts liver drug metabolism due to lipid accumulation. Understanding this interplay is crucial for tailoring drug dosages in NAFLD patients.
Area of Science:
- Hepatology
- Pharmacology
- Metabolic Syndrome
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a liver condition linked to metabolic syndrome, involving lipid buildup, lipotoxicity, and insulin resistance.
- NAFLD progression involves inflammation, oxidative stress, fibrosis, and apoptosis, potentially leading to liver cancer.
- The liver's role in metabolism means NAFLD affects both internal (endobiotic) and external (xenobiotic) compound processing.
Purpose of the Study:
- To review the intricate relationship between NAFLD development and drug metabolism.
- To highlight how altered nuclear receptor activity in NAFLD impacts drug processing.
- To emphasize the need for improved pharmacotherapy strategies in NAFLD.
Main Methods:
- Literature review focusing on NAFLD pathogenesis and drug metabolism.
- Analysis of studies on nuclear receptors, drug-metabolizing enzymes, and transporters in NAFLD.
- Examination of genetic and association studies linking drug metabolism to NAFLD prevalence and severity.
Main Results:
- Hepatic lipid accumulation in NAFLD deregulates nuclear receptors, altering drug metabolism.
- Dysfunctional drug metabolism pathways can influence the occurrence and severity of NAFLD.
- Nuclear receptors regulate both drug and lipid metabolism, creating a complex feedback loop.
Conclusions:
- Altered drug metabolism is a significant consequence of NAFLD pathogenesis.
- Understanding the NAFLD-drug metabolism interaction is essential for personalized pharmacotherapy.
- Developing precise drug dosing algorithms for NAFLD patients requires further research into these metabolic links.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...